The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.
February 7th 2025
These data suggest that dupilumab’s drug survival rate at 12 and 24 months is greater than that of upadacitinib and tralokinumab among patients with atopic dermatitis.